Prognostic value of plasma interleukin-6 concentrations and the -174 G > C and -572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis.
The present study was performed to investigate the prognostic value of plasma interleukin-6 (IL-6) concentrations and promoter polymorphisms of the IL-6 gene in patients with acute myocardial infarction treated with thrombolysis. Two hundred and eight patients with myocardial infarction treated with thrombolysis were included and followed for 2-5 years. Plasma concentrations of IL-6 were measured at admission and 48 h after admission. Genotyping for the -174 G > C and -572 G > C IL-6 polymorphisms was performed. Patients who died of cardiovascular causes or suffered a new myocardial infarction during follow-up had increased plasma concentrations of IL-6 at admission (P < 0.002) and at 48 h after admission (P < 0.05) compared with patients who had an uneventful course. IL-6 levels above the median at admission were independently associated with a worse prognosis. No associations were found between IL-6 levels and the promoter polymorphisms. The -174 G > C polymorphism was not associated with cardiovascular death or a new myocardial infarction, whereas the -572 G > C polymorphism showed a borderline significant increase in risk (P = 0.05) in univariate analysis. In conclusion, the early IL-6 response during myocardial infarction is associated with prognosis in patients with Q-wave myocardial infarction, whereas no associations were found between IL-6 genotype and phenotype.
Bennermo
Marie
M
Department of Medicine, Danderyd University Hospital, SE 182 88, Stockholm, Sweden. marie.bjornstedt-bennermo@med.ds.sll.se
Held
Claes
C
Green
Fiona
F
Strandberg
Lars-Erik
LE
Ericsson
Carl-Göran
CG
Hansson
Lars-Olof
LO
Watkins
Hugh
H
Hamsten
Anders
A
Tornvall
Per
P
D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D015331:Cohort Studies; D016001:Confidence Intervals; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D006334:Heart Function Tests; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D015850:Interleukin-6 / Q000097:blood* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011110:Polymorphism, Genetic; D011336:Probability; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000379:methods
D015415:Biomarkers; D005819:Genetic Markers; D015850:Interleukin-6; D002097:C-Reactive Protein; D003402:Creatine Kinase